Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade
Hannah Yang, … , Hong Jae Chon, Chan Kim
Hannah Yang, … , Hong Jae Chon, Chan Kim
Published July 25, 2019
Citation Information: J Clin Invest. 2019;129(10):4350-4364. https://doi.org/10.1172/JCI125413.
View: Text | PDF
Research Article Angiogenesis Immunology

STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade

  • Text
  • PDF
Abstract

The stimulator of IFN genes (STING) signaling pathway is a critical link between innate and adaptive immunity and induces antitumor immune responses. STING is expressed in vasculatures, but its role in tumor angiogenesis has not been elucidated. Here, we investigated STING-induced tumor vascular remodeling and the potential of STING-based combination immunotherapy. Endothelial STING expression was correlated with enhanced T cell infiltration and prolonged survival in human colon and breast cancer. Intratumoral STING activation with STING agonists (cGAMP or RR-CDA) normalized tumor vasculatures in implanted and spontaneous cancers, but not in STING-deficient mice. These were mediated by upregulation of type I/II IFN genes and vascular stabilizing genes (e.g., Angpt1, Pdgfrb, and Col4a). STING in nonhematopoietic cells is as important as STING in hematopoietic cells for inducing a maximal therapeutic efficacy of exogenous STING agonists. Vascular normalizing effects of STING agonists were dependent on type I IFN signaling and CD8+ T cells. Notably, STING-based immunotherapy was maximally effective when combined with VEGFR2 blockade and/or immune-checkpoint blockade (αPD-1 or αCTLA-4), leading to complete regression of immunotherapy-resistant tumors. Our data show that intratumoral STING activation can normalize tumor vasculature and the tumor microenvironment, providing a rationale for combining STING-based immunotherapy and antiangiogenic therapy.

Authors

Hannah Yang, Won Suk Lee, So Jung Kong, Chang Gon Kim, Joo Hoon Kim, Sei Kyung Chang, Sewha Kim, Gwangil Kim, Hong Jae Chon, Chan Kim

×

Figure 5

STING signaling pathway regulates tumor vascular and immune microenvironment.

Options: View larger image (or click on image) Download as PowerPoint
STING signaling pathway regulates tumor vascular and immune microenviron...
WT or STING-deficient mice (STINGgt/gt, KO) were injected with LLC tumor cells and treated with intratumoral injections of PBS or STING agonist. (A) Volcano plot showing gene-expression changes in STING agonist–treated tumors of WT mice (red) and PBS-treated tumors of STING-deficient mice (blue). (B–E) Comparison of gene expression related to type I/II IFNs (B), vascular stabilization (C), vascular destabilization (D), and endothelial cell (EC) and lymphocyte interaction (E). (F) Comparison of gene expression related to inhibitory and agonistic immune checkpoints in tumors treated with STING agonist. (G) Flow cytometric analyses of immune checkpoints in tumors. Pooled data from 2 experiments with n = 4 to 9 per group. Values are shown as mean ± SD. *P < 0.05 versus PBS. Two-tailed Student’s t test (B–G).
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts